Prof. Dr. Christoph Driessen
Chefarzt Klinik für Medizinische Onkologie und Hämatologie, Kantonsspital St.Gallen
Stellvertretender Leiter Comprehensive Cancer Center Kantonsspital St.Gallen
Medizinische Onkologie und Hämatologie · Dept. I
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016
16.12.2016Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
16.12.2016Br J Haematol 2016
Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph
Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.
01.08.2016Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
01.08.2016J Med Chem 2016; 59:7177-87
Xin Bo-Tao, Groll Michael, Driessen Christoph, van der Stelt Mario, Kisselev Alexei F, van der Marel Gijsbert A, Filippov Dmitri V, Florea Bogdan I, Besse Andrej, Huber Eva M, de Bruin Gerjan, Overkleeft Herman S
Multiple myeloma: patient outcomes in real-world practice
Yong K, Schoen P, Raab M, Mateos M, Karlin L, Safaei R, Gonzalez-McQuire S, Flinois A, Fink L, Driessen C, Delforge M, Cavo M. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016; 175:252-264.
13.07.2016Multiple myeloma: patient outcomes in real-world practice
13.07.2016Br J Haematol 2016; 175:252-264
Yong Kwee, Schoen Paul, Raab Marc S, Mateos Maria-Victoria, Karlin Lionel, Safaei Reza, Gonzalez-McQuire Sebastian, Flinois Alain, Fink Leah, Driessen Christoph, Delforge Michel, Cavo Michele
Multiple myeloma: practice patterns across Europe
Raab M, Schoen P, Mateos M, Karlin L, Safaei R, Gonzalez-McQuire S, Flinois A, Fink L, Driessen C, Delforge M, Cavo M, Yong K. Multiple myeloma: practice patterns across Europe. Br J Haematol 2016; 175:66-76.
13.06.2016Multiple myeloma: practice patterns across Europe
13.06.2016Br J Haematol 2016; 175:66-76
Raab Marc S, Schoen Paul, Mateos Maria-Victoria, Karlin Lionel, Safaei Reza, Gonzalez-McQuire Sebastian, Flinois Alain, Fink Leah, Driessen Christoph, Delforge Michel, Cavo Michele, Yong Kwee
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2016; 76:989-990.
01.06.2016Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
01.06.2016Drugs 2016; 76:989-990
Moreau Philippe, Ludwig Heinz, Driessen Christoph, Palumbo Antonio, Facon Thierry, Plesner Torben, Dimopoulos Meletios, Sondergeld Pia, Sonneveld Pieter, Zweegman Sonja, Einsele Hermann, van de Donk Niels W C J, Miguel Jesus San, Lokhorst Henk, Nahi Hareth, Ben-Yehuda Dina, Cavo Michele, Cook Gordon, Delforge Michel, Mateos Maria-Victoria
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2016; 76:853-67.
01.05.2016Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
01.05.2016Drugs 2016; 76:853-67
Moreau Philippe, Ludwig Heinz, Driessen Christoph, Palumbo Antonio, Facon Thierry, Plesner Torben, Dimopoulos Meletios, Sondergeld Pia, Sonneveld Pieter, Zweegman Sonja, Einsele Hermann, van de Donk Niels W C J, San Miguel Jesús, Lokhorst Henk, Nahi Hareth, Ben-Yehuda Dina, Cavo Michele, Cook Gordon, Delforge Michel, Mateos Maria-Victoria
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
Soriano G, Florea B, Overkleeft H, den Dulk H, Everts B, Bader J, Meeuwenoord N, Besse A, Kraus M, Li N, Besse L, Driessen C. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 2016; 30:2198-2207.
27.04.2016Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
27.04.2016Leukemia 2016; 30:2198-2207
Soriano G P, Florea B I, Overkleeft H S, den Dulk H, Everts B, Bader J, Meeuwenoord N, Besse A, Kraus Marianne, Li N, Besse L, Driessen Christoph
Development of new Malt1 inhibitors and probes
Xin B, Schimmack G, Du Y, Florea B, van der Marel G, Driessen C, Krappmann D, Overkleeft H. Development of new Malt1 inhibitors and probes. Bioorg Med Chem 2016; 24:3312-29.
28.03.2016Development of new Malt1 inhibitors and probes
28.03.2016Bioorg Med Chem 2016; 24:3312-29
Xin Bo-Tao, Schimmack Gisela, Du Yimeng, Florea Bogdan I, van der Marel Gijsbert A, Driessen Christoph, Krappmann Daniel, Overkleeft Herman S
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
11.12.2015Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
11.12.2015Haematologica 2015; 101:346-55
Driessen Christoph, Hess Dagmar, von Moos Roger, Pabst Thomas, Huitema Alwin, Sessa Christiana, Overkleeft Hermann S, Berthod Gregoire, Hawle Hanne, Xyrafas Alexandros, Berset Catherine, Hitz Felicitas, Bader Jürgen, Rosing Hilde, Jörger Markus, Kraus Marianne, Mey Ulrich J M
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
de Bruin G, Xin B, Kraus M, van der Stelt M, van der Marel G, Kisselev A, Driessen C, Florea B, Overkleeft H. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. Angew Chem Int Ed Engl 2015; 55:4199-203.
29.10.2015A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
29.10.2015Angew Chem Int Ed Engl 2015; 55:4199-203
de Bruin Gerjan, Xin Bo Tao, Kraus Marianne, van der Stelt Mario, van der Marel Gijsbert A, Kisselev Alexei F, Driessen Christoph, Florea Bogdan I, Overkleeft Herman S
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
06.07.2015Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
06.07.2015J Clin Oncol 2015; 33:2523-9
Mamot Christoph, Zucca Emanuele, Dirnhofer Stephan, Rusterholz Corinne, Biaggi Christine, Samarin Andrei, Hany Thomas, Gigli Federica, Krasniqi Fatime, Bargetzi Mario, Pless Miklos, Mey Ulrich, Driessen Christoph, Pabst Thomas, Renner Christoph, Hitz Felicitas, Klingbiel Dirk, Martinelli Giovanni
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol 2015; 76:383-96.
23.06.2015The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
23.06.2015Cancer Chemother Pharmacol 2015; 76:383-96
Kraus Johannes, Kraus Marianne, Liu Nora, Besse Lenka, Bader Jürgen, Geurink Paul P, de Bruin Gerjan, Kisselev Alexei F, Overkleeft Herman, Driessen Christoph
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
11.06.2015The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
11.06.2015Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph
Improved survival of older patients with multiple myeloma in the era of novel agents
Mey U, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2015; 34:217-223.
21.04.2015Improved survival of older patients with multiple myeloma in the era of novel agents
21.04.2015Hematol Oncol 2015; 34:217-223
Mey Ulrich J M, Leitner Christoph, Driessen Christoph, Cathomas Richard, Klingbiel Dirk, Hitz Felicitas
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
Tornatore L, Dyson J, Walker B, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Thotakura A, Jaxa-Chamiec A, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Franzoso G. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors. Cancer Cell 2014; 26:495-508.
13.10.2014Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
13.10.2014Cancer Cell 2014; 26:495-508
Tornatore Laura, Dyson Julian, Walker Brian A, Leonardi Antonio, Chambery Angela, Driessen Christoph, Sonneveld Pieter, Morgan Gareth, Palumbo Antonio, Tramontano Anna, Rahemtulla Amin, Ruvo Menotti, Thotakura Anil K, Jaxa-Chamiec Albert, Sandomenico Annamaria, Raimondo Domenico, Low Caroline, Rocci Alberto, Tralau-Stewart Cathy, Capece Daria, D'Andrea Daniel, Bua Marco, Boyle Eileen, van Duin Mark, Zoppoli Pietro, Franzoso Guido
Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes
de Bruin G, Groll M, van der Marel G, van der Stelt M, Driessen C, Kisselev A, Kim K, Al-Ayed K, van Rooden E, Xin B, Huber E, Overkleeft H. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem 2014; 57:6197-209.
15.07.2014Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes
15.07.2014J Med Chem 2014; 57:6197-209
de Bruin Gerjan, Groll Michael, van der Marel Gijsbert A, van der Stelt Mario, Driessen Christoph, Kisselev Alexei F, Kim Kyung-Bo, Al-Ayed Karol, van Rooden Eva J, Xin Bo-Tao, Huber Eva M, Overkleeft Herman S
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Engelhardt M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos M, Einsele H, Sonneveld P, Palumbo A, Beksac M, Ludwig H, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen H, Hájek R, Driessen C, European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99:232-42.
01.02.2014European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
01.02.2014Haematologica 2014; 99:232-42
Engelhardt Monika, Boccadoro Mario, Straka Christian, Brighen Sara, Gramatzki Martin, Larocca Alessandra, Lokhorst Henk, Magarotto Valeria, Morabito Fortunato, Dimopoulos Meletios A, Einsele Hermann, Sonneveld Pieter, Palumbo Antonio, Beksac Meral, Ludwig Heinz, Terpos Evangelos, Kleber Martina, Gay Francesca, Wäsch Ralph, Morgan Gareth, Cavo Michele, van de Donk Niels, Beilhack Andreas, Bruno Benedetto, Johnsen Hans Erik, Hájek Roman, Driessen Christoph, European Myeloma Network
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H, Driessen C. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res 2013; 38:383-92.
25.12.2013Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
25.12.2013Leuk Res 2013; 38:383-92
Kraus Marianne, Müller-Ide Hendrik, Rückrich Thomas, Bader Jürgen, Overkleeft Herman, Driessen Christoph
Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells
Auner H, Karadimitris A, Apperley J, Rahemtulla A, Dazzi F, Cenci S, Driessen C, Chaidos A, May P, Milan E, Kraus M, Ward T, Moody A, Dillon N. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PloS one 2013; 8:e74415.
17.09.2013Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells
17.09.2013PloS one 2013; 8:e74415
Auner Holger W, Karadimitris Anastasios, Apperley Jane F, Rahemtulla Amin, Dazzi Francesco, Cenci Simone, Driessen Christoph, Chaidos Aristeidis, May Philippa, Milan Enrico, Kraus Marianne, Ward Theresa H, Moody Anne Marie, Dillon Niall
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 2013; 3:e103.
01.03.2013Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
01.03.2013Blood Cancer J 2013; 3:e103
Kraus Marianne, Bader J, Overkleeft H, Driessen Christoph